WASHINGTON, Feb. 19, 2020
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:
VNDA) announces the appointment of Stephen
Ray Mitchell, M.D. to its Board of Directors.
"Ray is a highly respected leader in academic medicine and
globally recognized expert in Pediatrics," said Mihael H. Polymeropoulos, M.D., President and
Chief Executive Officer of Vanda. "He brings a wealth of
operational and clinical expertise, and a strong governance
background. His diverse experiences across the clinical landscape
will assist us in the advancement of our pipeline and product
development."
Dr. Mitchell currently serves as the Joseph Butenas Professor
and Dean for Medical Education at Georgetown
University School of Medicine, a position he has held since
August 2002. Prior to that, Dr.
Mitchell served as Associate Dean for Clinical Curriculum at
Georgetown University School of
Medicine from 1998 to 2000 and as Senior Associate Dean for
Academic Affairs from 2000 until 2002.
"Ray is a gifted medical leader and will bring critical
scientific insights to the Board, which will be beneficial as we
work towards the commercialization of new therapies," said H.
Thomas Watkins, Chairman of the
Board of Directors. "We are looking forward to leveraging his
notable background to achieve our business objectives."
Previously, Dr. Mitchell served as Program Director for Internal
Medicine at Georgetown University School of
Medicine from 1992 until 1997, and as Founding Program
Director Med-Peds at Georgetown from 1995 until 1999. He served as
a member of the Liaison Committee for Medical Education (LCME), the
national accrediting body for Medical Schools in the United States and Canada, between 2013 and 2019. Since 2018, he
has held the role of Chair of the LCME, where he chaired the
Standards subcommittee, and now serves as a member of the Governing
Council of that body.
Dr. Mitchell is a veteran of the United States Air Force, and
has served as author and invited external reviewer on Studies by
the Institute of Medicine on Chronic Multi-symptoms illness in Gulf
War veterans. He has been inducted into the Magis Society at
Georgetown, the Hall of Fame for Teachers, after 20 years on
faculty. In 2011, the University of North
Carolina School of Medicine awarded Dr. Mitchell the
Distinguished Alumni Award. In 2019, he was inducted as Fellow of
the Royal College of Physicians of London.
Dr. Mitchell received his B.A. in Psychology and his M.D. from
the University of North Carolina at Chapel
Hill, and completed his residency and chief residency in
Medicine and Pediatrics at North Carolina Memorial Hospital. He
completed his Rheumatology subspecialty training at the School of
Medicine at Georgetown University and his Global Executive
M.B.A. at The McDonough School of Business at Georgetown University.
Dr. Mitchell joined Vanda's Board of Directors, on February 14th, filling the vacancy
created by the departure of Michael F.
Cola.
About Vanda Pharmaceuticals Inc.
Vanda is a
global biopharmaceutical company focused on the development and
commercialization of innovative therapies to address high unmet
medical needs and improve the lives of patients. For more on Vanda
Pharmaceuticals Inc., please visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release, including, without
limitation, statements regarding Dr. Mitchell's ability to assist
Vanda in advancing its pipeline and product development and
achieving its business objectives, are "forward-looking statements"
under the securities laws. Forward-looking statements are based
upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others, Vanda's assumptions regarding its ability to complete the
clinical development and obtain regulatory approval for the
products in its pipeline and other factors that are set forth in
the "Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of Vanda's
annual report on Form 10-K for the fiscal year ended December 31, 2018 and quarterly report on Form
10-Q for the fiscal quarter ended September
30, 2019, which are on file with the SEC and available on
the SEC's website at www.sec.gov. Additional factors may be set
forth in those sections of Vanda's annual report on Form 10-K for
the fiscal year ended December 31,
2019, to be filed with the SEC in the first quarter of 2020.
In addition to the risks described above and in Vanda's annual
report on Form 10-K and quarterly reports on Form 10-Q, other
unknown or unpredictable factors also could affect Vanda's results.
There can be no assurance that the actual results or developments
anticipated by Vanda will be realized or, even if substantially
realized, that they will have the expected consequences to, or
effects on, Vanda. Therefore, no assurance can be given that the
outcomes stated in such forward-looking statements and estimates
will be achieved.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this release is provided
only as of the date of this release, and Vanda undertakes no
obligation, and specifically declines any obligation, to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Corporate Contact:
AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-appoints-stephen-ray-mitchell-to-board-of-directors-301006968.html
SOURCE Vanda Pharmaceuticals Inc.